Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Kamux Group Management Team Will Be Renewed and Strengthened

Kamux Corporation       Stock Exchange Release         January 4, 2022 at 08:00 (EET) Kamux Group Management Team Will Be Renewed and Strengthened The composition and responsibilities of Kamux Corporation’s Group Management Team will be renewed and strengthened to support the implementation of the updated strategy announced in March 2021. The strategic growth objective and internationalization require a new composition and expertise in the Group Management Team. The work of the Group Management Team will be re-organised, and in addition to the previously announced, there will be

Selvaag Bolig ASA: Status for buyback of own shares for employee share purchase programmes

As announced 6 December 2021 Selvaag Bolig ASA has initiated repurchase of up to 500 000 shares for the company’s incentive programmes. From 28 December 2021 through 3 January 2022 the company bought 66 095 shares at an average price of NOK 51.85. See the attached documents for detailed information about the transactions made. The buyback is carried out in accordance with the EU Market Abuse Regulation and Safe Harbour Regulation. Daily purchases are limited to a maximum of 25 per cent of the average daily volume traded the last 20 days. Following these transactions, Selvaag Bolig

UNION therapeutics announces enrollment of first patient in the IASOS Phase 2b study of oral orismilast in psoriasis patients

· IASOS[ ]is a Phase 2b dose-ranging study of oral orismilast in psoriasis patients with the purpose of identifying the appropriate dose-regimen for Phase 3 studies · Orismilast is a next generation PDE4 inhibitor with broad anti-inflammatory properties also in development for the treatment of hidradenitis suppurativa (HS) and atopic dermatitis (AD)   Hellerup, Denmark, 4 January 2022 – UNION therapeutics A/S, a privately-held, multi-asset, clinical stage, biotechnology company focused on immunology and infectious diseases, today announced that the first patient has been enrolled in

Injeq’s IQ-Tip® needle receives CE certification – the Finnish innovation is ready for sales to the European market

Injeq Oy Press releaseJanuary 4, 2022 at 7:00 a.m. EET     The medical technology company Injeq’s development yielded the desired outcome after many years of efforts as the company’s IQ-Tip® needle received CE approval on December 21, 2021. The needle can be used in lumbar punctures from newborns to the elderly, treatment punctures of children with leukemia being one of the main indications. For medical devices, the CE certification translates to a marketing authorization in Europe. In other words, the company can expect a new era of growth as a result of the certification.

Acquires portfolio of 126 rental apartments in Umea

KlaraBo acquires a residential portfolio in Umea of a total of 126 rental apartments with an underlying property value of SEK 175 million. The total area amounts to approximately 8,700 sqm and the portfolio will be taken over today. The property portfolio is centrally located in Umea and fully rented. The rental value amounts to SEK 10.2 million and consists almost exclusively of residential and parking income. The acquisition is financed by bank loans and own cash. The acquisition also means that KlaraBo will establish itself in a new location for the company. "It feels good to

Nordea Bank Abp: Repurchase of own shares on 03.01.2022

Nordea Bank AbpStock exchange release – Changes in company’s own shares03.01.2022 at 22.30 EET Nordea Bank Abp (LEI: 529900ODI3047E2LIV03) has on 03.01.2022 completed repurchases of own shares (ISIN: FI4000297767) as follows: Trading Number of Weighted average Total cost, EUR* **venue (MIC shares price / share, EUR* Code) **XSTO 350,560 10.85 3,804,588.74XHEL 262,351 10.87 2,851,125.73CEUX 299,740 10.86 3,255,532.36AQEU 50,992 10.86

Hansa Biopharma enters into agreement with AskBio to evaluate feasibility of imlifidase as pre-treatment ahead of gene therapy in Pompe disease

Collaboration to evaluate imlifidase as potential pre-treatment prior to the administration of gene therapy in Pompe disease for patients with neutralizing antibodies (NAbs) to adeno-associated virus (AAV)Lund, Sweden January 3, 2022. Hansa Biopharma AB, “Hansa”, (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced that it has entered into an agreement with Asklepios BioPharmaceutical, Inc. (“AskBio”), a fully integrated AAV gene therapy company and a fully owned subsidiary of Bayer AG dedicated to developing medicines that improve the

Announcement of a change in shareholding according to Chapter 9, Section 10 of the Finnish Securities Market Act

Nixu Corporation, Stock exchange release on January 3, 2022 at 19.00 EETNixu Corporation has received a notification pursuant to Chapter 9, Section 5 of the Securities Markets Act from Aktia Rahastoyhtiö Oy on January 3, 2022. According to the notification, the aggregate ownership of Aktia Mikro Markka, Aktia Nordic Micro Cap, Aktia Nordic Small Cap, Aktia Secura investment funds, managed by Aktia Rahastoyhtiö Oy, in Nixu Corporation’s shares (ISIN: FI0009008387) increased above five (5) per cent threshold on January 1, 2022. Nixu has one share series and each share entitles its

ALEXANDRIA PANKKIIRILIIKE OYJ: ACQUISITION OF OWN SHARES 03.01.2022

ALEXANDRIA PANKKIIRILIIKE OYJ NOTIFICATION 03.01.2022 at 18:30 EET ALEXANDRIA PANKKIIRILIIKE OYJ: ACQUISITION OF OWN SHARES 03.01.2022 Date 03.01.2022Exchange transaction BuyShare class ALEXAmount 396Average price/share 8.3642 EURHighest price/share 8.3800 EURLowest price/share 8.2200 EURTotal price 3,312.22 EUR The shares held by Alexandria Pankkiiriliike Oyj on 03.01.2022: ALEX 45,871 On behalf of Alexandria Pankkiiriliike Oyj  Skandinaviska Enskilda Banken AB (Publ)

UNITED BANKERS PLC: ACQUISITION OF OWN SHARES 03.01.2022

United Bankers Plc NOTIFICATION 03.01.2022 at 18:30 UNITED BANKERS PLC: ACQUISITION OF OWN SHARES 03.01.2022 Date 03.01.2022Exchange transaction BuyShare class UNITEDAmount 488Average price/share 14.3500 EURHighest price/share 14.3500 EURLowest price/share 14.3500 EURTotal price 7,002.80 EUR The shares held by United Bankers Plc on 03.01.2022: UNITED 57,969 On behalf of United Bankers Plc  Skandinaviska Enskilda Banken AB (Publ) Antti Salakka         Janne Tiihonen For

#22-2 Delisting of Derivatives from NGM

Information about certain derivatives that will be delisted from NGM.For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on phone +46 8 566 390 20 or listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a

#22-1 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGMFor more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on phone +46 8 566 390 20 or listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a

Smoltek extends evaluation agreement with global manufacturer of capacitors

This press release is an English version of the previously published Swedish version, which has interpretive precedence. Smoltek Nanotech Holding AB (“Smoltek”) announces that the evaluation agreement that the company signed in April 2020 with a large manufacturer of electronic components has been extended further until the end of February 2022. The work within this project is carried out in the subsidiary Smoltek Semi, whose main objective is to develop and license the manufacture of extremely small and thin capacitors based on Smoltek's patent-protected carbon nanofiber technology.

Buybacks of shares in Alfa Laval during week 52, 2021

During the period December 27 – December 30, 2021, Alfa Laval AB (publ) (LEI code: 549300UCKT2UK88AG251) has repurchased in total 78,000 own shares (ISIN: SE0000695876) as part of the share buyback program initiated by the Board of Directors in order to secure optimized capital structure.The share buybacks form part of the SEK 2 billion share buyback program, which Alfa Laval announced on April 27, 2021. The share buy-back program, which runs between April 28, 2021 and April 25, 2022, is being carried out in accordance with the EU Market Abuse Regulation (MAR) and the Commission Delegated

Invitation to Pexip Q4 2021 ARR Update

Oslo, Norway, January 3, 2022: Pexip Holding ASA ("Pexip" or "the Company", Oslo Børs Ticker: PEXIP) will release its Q4 2021 ARR update on January 10, 2022, at 07:00 CET. The Company will also hold a short presentation of the ARR update on January 10, 2022, at 08:00 CET. The webcast will be available on investor.pexip.com. The presentation will be held by Øystein Dahl Hem, Interim CEO and CFO, and Åsmund Olav Fodstad, President Global Sales & Marketing.  For further information, please contact:  Investors: Investor Relations, IR@pexip.com, +47 94 80 58 51  Media: Lars-Einar

Buybacks of series B shares in AB Electrolux during week 52, 2021

Stockholm, Sweden, January 3, 2022 During the period December 27 – December 30, 2021 AB Electrolux (LEI code 549300Y3HHZB1ZGFPJ93) has repurchased in total 342,312 own series B shares (ISIN: SE0016589188) as part of the buyback program initiated by the Board of Directors in order to optimize the company’s capital structure.The share buybacks form part of the buyback program of a maximum of 9,369,172 series B shares for a total maximum amount of SEK 2,800 million, which AB Electrolux announced on October 27, 2021. The buyback program, which runs between October 28, 2021 – March 25, 2022,

Acquisition expands Assemblin’s electrical engineering operations in Turku, Finland

Assemblin in Finland is acquiring the operations of electrical engineering company Sähköpalvelu J. Vainionpää Oy. With the acquisition, Assemblin is strengthening its position in Turku, expanding the current installation operations with additional electrical engineering expertise and approximately SEK 15 million in annual sales.Sähköpalvelu J. Vainionpää Oy (“Sähköpalvelu J. Vainionpää”), which was founded in 1992, employs ten electricians and operates mainly in Turku and its environs in south-western Finland. The company has annual sales of approximately SEK 15 million and works

Humana acquires individual and family company Kalliola Oy

Humana acquires the Finnish individual and family company Kalliola Oy. The acquisition will strengthen Humana’s position in the Helsinki Metropolitan Area region in Finland and will increase Humana’s capacity to provide care services for children, youth and adults as the needs in society is increasing.Kalliola Oy is part of the Kalliola Group and owned by the Kalliola Settlement Association which has operated in Finland for hundred years. Kalliola Oy provides child welfare services, housing services and open care services. Full-year revenues amount to approximately EUR 9 million,

BioStock: Chordate Medical closed 2021 with focus on Saudi Arabia

Patients with chronic nasal congestion in Saudi Arabia can receive full reimbursement for Chordate Medical’s K.O.S treatment, which was recently performed for the first time on a privately insured patient. In addition, Chordate Medical’s management has just returned from a business trip in Saudi Arabia where they visited several healthcare providers using K.O.S, as well as a big conference in Otolaryngology. BioStock contacted CEO Anders Weilandt to hear more about the business travel and progress in Saudi Arabia.Read the full article at biostock.se: https://www.biostock.se/en/2022/01/

Oterra continues its growth track with the acquisition of Food Ingredient Solutions

Oterra, the world’s leading supplier of natural colors, with the widest portfolio in the industry, continues its strong growth acceleration announcing today the acquisition of Food Ingredient Solutions.Founded in 1999, Food Ingredient Solutions is a leading American producer of colors and natural antioxidants, with a strong exposure to, and growth from, natural colors. The Company serves more than 400 customers annually and has two certified processing facilities located in Teterboro, New Jersey, and Marshfield, Missouri.Oterra continues its strong growth with multiple complementary bolt-

Clinical Laserthermia Systems AB Promotes Michael Magnani to President of its U.S Subsidiary, CLS Americas Inc.

Clinical Laserthermia Systems AB (publ) (CLS AB), developer of high precision, image-guided focal laser ablation (FLA) systems, today announced it has promoted Mr. Michael Magnani to president of its U.S subsidiary Clinical Laserthermia Systems Americas Inc. (CLS Americas). Mr. Magnani previously served two years as the managing director and is succeeding Mr. Dan J. Mogren, who will be joining CLS Americas’ board of directors.CLS Americas is focused on supporting postmarket studies and managing the commercialization of the TRANBERG® | Thermal Therapy Systems as image-guided precision tools

Componenta Corporation: Managers’ Transactions

Componenta Corporation Stock Exchange Release, 3 January 2022 at 1.30 p.m. EET Componenta Corporation has received the following notification of managers’ transactions with Componenta’s shares. Person subject to the notification requirementName: Sivuranta, SamiPosition: Chief Executive OfficerIssuer: Componenta CorporationLEI: 5493000SDCOXVGZDWK18 Notification type: INITIAL NOTIFICATIONReference number: 5493000SDCOXVGZDWK18_20211230130416_28____________________________________________ Transaction date: 2021-12-30Venue not applicableInstrument type: SHAREISIN:

Componenta Corporation: Managers’ Transactions

Componenta Corporation Stock Exchange Release, 3 January 2022 at 1.30 p.m. EET Componenta Corporation has received the following notification of managers’ transactions with Componenta’s shares. Person subject to the notification requirementName: Mäkinen, PasiPosition: Other senior managerIssuer: Componenta CorporationLEI: 5493000SDCOXVGZDWK18 Notification type: INITIAL NOTIFICATIONReference number: 5493000SDCOXVGZDWK18_20211230130416_29____________________________________________ Transaction date: 2021-12-30Venue not applicableInstrument type: SHAREISIN:

There are no items matching the current filter
There are no more items matching the current filter
Back to top